Dr. Michael Har-Noy Discusses His Upcoming Phase I/II trial of CRCL-AlloVaxTM

18 Jan

Dr. Michael Har-Noy, founder and C.E.O. of Immunovative Therapies, Ltd., will soon conduct a Phase I/II clinical trial of CRCL-AlloVaxTM, a novel anti-cancer vaccine.  Dr. Michael Har-Noy indicates that this new drug will likely have activity against many different tumor types.   He will conduct the study in Thailand as part of a “Compassionate Use Program” (CUP). The study gives metastatic cancer patients an experimental treatment option after conventional methods have failed.  Interest patients may enroll at www.immunocare.net.

Dr. Michael Har-Noy says that the study will test the effects of CRCL-AlloVax™ against a variety of different tumor types. The vaccine is designed to teach the patient’s immune system to recognize and kill malignant cells that were previously able to avoid the host immune response.  Dr. Michael Har-Noy hopes this will result in a minimally toxic yet effective treatment for metastatic cancer patients, thereby leading to increased survival and a better quality of life.  However, Dr. Michael Har-Noy indicates that at this time it is unknown if and how well patients will respond to CRCL-AlloVax™.  This preliminary study will result in data that may be used to determine which types of malignancies respond best to this vaccine.  Dr. Michael Har-Noy adds that this study data will likely uncover other factors predictive of response, such as tumor size and location, immune status, and prior cancer therapies.

Dr. Michael Har-Noy states that while this experimental anti-cancer vaccine may result in increased longevity for many types of cancer patients, there is currently insufficient data to make any claims about its ultimate efficacy.   He adds that most currently available cancer drugs work only for some patients and usually have very significant side-effects.

In a previously conducted Phase I/II trial of AlloStimTM, one of the components of CRCL-AlloVaxTM, 42 patients with various tumors were given AlloStimTM  and had almost triple the estimated survival of historic control patients.  Dr Michael Har-Noy says that these non-randomized but very encouraging results will soon be detailed in a peer-reviewed journal.

Source: www.immunocare.net


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: